UroGen Pharma begins Phase 1 treatment in NMIBC: Will URGN hold $32.4 support?

UroGen Pharma begins Phase 1 treatment in NMIBC: Will URGN hold $32.4 support?
UroGen Pharma stock falls 2.2% today

UroGen Pharma announced that its first patient has started treatment in a Phase 1 study of UGN-501 for non-muscle invasive bladder cancer. The stock is down 2.2% on the day at $32.72.

Highlights

  • UroGen Pharma began dosing the first patient in a Phase 1 trial of investigational therapy UGN-501 for non-muscle invasive bladder cancer.
  • Shares of UroGen Pharma fell 2.2% to $32.72 with a market value near $1.8 billion and trailing revenue of $188.7 million.
  • 28 of 32 analysts rate the stock a buy, with a median price target of $59 and none assigning a sell rating.

UroGen Pharma announced that the first patient has begun treatment in its Phase 1 trial testing UGN-501. The therapy is described as a next-generation investigational oncolytic virus being evaluated in non-muscle invasive bladder cancer. The company employs 300 people, operates in biotechnology, and holds a market value near $1.8 billion on trailing revenue of $188.7 million.

Split daily structure as price holds above long-term support

The session opened with a gap down from $33.48 to $33.14, placing immediate pressure on shares of UroGen Pharma. Price is now below the MA-20 and MA-50 but remains above the MA-200, reflecting a split daily structure. The nearest support is the weekly low at $32.4. RSI at 26.1 indicates oversold conditions, which limits room for further downside after a sustained move lower with a firm trend over the past week.

Downside odds dominate as traders focus on $32.4 support level

To confirm whether the recent developments are being absorbed by the market, traders should watch for a close above $34.95 or a break below $32.4. Shares opened below the previous close, dropping from $33.48 to $33.14 at the start of the session. Looking ahead over the coming trading week, there is a 23% probability of upside and a 77% probability of downside, with the price expected to range between $31.57 and $33.86. Even so, a close above $34.95 would show buyers are willing to follow through, while a drop below $32.4 would show the move is being faded. On the weekly chart the longer-term picture stays constructive.

Earlier, analysts noted that UroGen Pharma's technical outlook had shifted to increased downside risk as shares hovered near key support. The initiation of the UGN-501 Phase 1 trial adds a clinical milestone, but with the price now below short-term moving averages and testing lower support, ongoing traders should watch for a decisive move below $32.4 or a close above $34.95 to gauge near-term direction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.